Evidence map›Paper›PMID 40307430›Full record

ArticleScientific reports2025

Efficient atrazine degradation through ZnFe

Junyi Gao, Xuying Zhao, Caibin Li, Zhenbao Luo, Long Zhang, Zhipeng Xiao, Tingting Mu, Furong Liu, Ruikang Gao, Jiguang Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Recent Advances of g-CMolecules (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Junyi Gao *Bijie Tobacco Branch Company of Guizhou Province, Bijie, 551700, China.
Xuying Zhao *Tobacco Research Institute, Chinese Academy of Agricultural Sciences, Qingdao, 266101, China.
Caibin LiBijie Tobacco Branch Company of Guizhou Province, Bijie, 551700, China.
Zhenbao LuoBijie Tobacco Branch Company of Guizhou Province, Bijie, 551700, China.
Long ZhangBijie Tobacco Branch Company of Guizhou Province, Bijie, 551700, China.
Zhipeng XiaoHengyang Tobacco Company of Hunan Province, Hengyang, 421001, China.
Tingting MuHengyang Tobacco Company of Hunan Province, Hengyang, 421001, China.
Furong LiuTobacco Research Institute, Chinese Academy of Agricultural Sciences, Qingdao, 266101, China.
Ruikang GaoTobacco Research Institute, Chinese Academy of Agricultural Sciences, Qingdao, 266101, China.
Jiguang ZhangTobacco Research Institute, Chinese Academy of Agricultural Sciences, Qingdao, 266101, China. zhangjiguang@caas.cn.
Xiwen SunBijie Tobacco Branch Company of Guizhou Province, Bijie, 551700, China. 362539829@qq.com.

Funding

Agricultural Science and Technology Innovation Program of China ASTIP-TRIC06the Science and Technology Project of Bijie Tobacco Branch Company 2020520500240072, 2023520500240162the Science and Technology Project of Hengyang Tobacco Company of Hunan Province 2020430400240090
6 · The paper itself

Abstract

Atrazine (ATZ) is widely used as an herbicide in agricultural production. However, its extensive application results in contaminated residues that can adversely affect ecosystems because rainwater washes them into and contaminates water bodies. Therefore, there is a pressing need to remove ATZ from the aquatic environment. Using transition metals as catalysts for the persulfate degradation of organic pollutants has received much attention because of their strong ability to oxidize pollutants, including ATZs, and their selectivity for these pollutants. A novel technique for ATZ removal using a catalyst (ZnFe

Indexed as

AtrazineCatalytic oxidationFree radicalsPeroxymonosulfateZnFe2O4

Identifiers

PMID40307430
PMCPMC12043815

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.